Results of neoadjuvant chemotherapy (NCT) in ER-positive Her-2/neu negative stage II-III breast cancer after 2, 4, 6 and 8 courses
Abstract
Background: Neoadjuvant chemotherapy is optimal treatment of ER-positive Her-2/neu negative breast cancer. We evaluated results after 2, 4, 6, and 8 courses.
Methods: We provided a retrospective analysis of the effectiveness of 2-8 courses of NCT (121 patients). NCT consisted of doxorubicin and endoxan and docetaxel. After NCT all patient received surgery, radiation and ET.
Results: In the group 2 in 1 case (4%) wasn’t effect of treatment, in 6 (23%) cases there were a PR and in 19 (73%) cases - stabilization. In the group with 4 courses in 2 case (6.5%) wasn’t effect, in 15 (48.4%) cases were PR and in 13 (41.9%) cases - stabilization. In 1 (3.1%) case - pCR. In the group with 6 courses in 1 case (3.1%) wasn’t effect, in 18 (56.3%) cases there were PR and in 8 (25%) cases - stabilization. In 5 (15.6%) cases, there were pCR. In the last group in 1 case (3.1%) there wasn’t effect of treatment, in 18 (56.3%) cases there were PR and in 4 (12.5%) cases - stabilization. In 9 (28.1%) cases, there were a pCR. The 5-year cancer-specific survival was from 88.1±6.4% to 96.8±3.2%.
Conclusion: 2 courses of NHT wasn’t effective. Tumor progression was in 3-6%. The growth of the Ki-67 index was in the range of 9.4-22.6%, pCR appeared in 3.2-15.6% of cases after 4-6 courses. An intermediate biopsy of the tumor will detect cases of resistance or high sensitivity tumors.
Full text article
References
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 Oct;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023.
Breast cancer. NCCN, version 3.2025, Available from:https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther. 2020;14:2423-2433. doi:10.2147/DDDT.S253961.
Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer a systematic review and meta-analysis. JAMA Oncol. 2016;2:1477–86. doi:10.1001/jamaoncol.2016.1897.
Sella T, Weiss A, Mittendorf EA, King TA, Pilewskie M, Giuliano AE, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol.т2021;7:1700–8. doi:10.1001/jamaoncol.2021.2132.
Lerebours F, Pulido M, Fourme E, Debled M, Becette V, Bonnefoi H, et al. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine thera-py: pooled analysis of two phase 2 trials. Br J Cancer. 2020;122:759–65. DOI: 10.1038/s41416-020-0733-x
López-Velazco JI, Manzano S, Otaño M, et al. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer. Breast Cancer Res 26, 3 (2024). doi:10.1186/s13058-023-01756-8.
Karahan F, Yılmaz Bozok Y, Gökova M, Gürsoy Bulut M, Bolat Küçükzeybek B, Atahan MK. Clinicopathologic Characteristics of Breast Cancer Patients Who Had a Pathologic Complete Response after Neoadjuvant Treatment. Ann Ital Chir. 2024;95(6):1240-1248. doi: 10.62713/aic.3403.
Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol. 2019;30:921–6. doi: 10.1093/annonc/mdz055.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neo-adjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049–60. doi: 10.1200/JCO.2015.63.1010.
Gentile D, Sagona A, De Carlo C, Fernandes B, Barbieri E, Di Maria Grimaldi S, et al. Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients. Breast. 2023 Jun;69:323-329. doi: 10.1016/j.breast.2023.03.016.
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081.
Allison KH, Hammond MEH, Dowsett M, McKerninSE, Carey LA, Fitzgibbons PL, et al. Estrogen and Pro-gesterone Receptor Testing in Breast Cancer: ASCO/CAPGuideline Update. Journal of Clinical Oncology: Offi-cial Journal of the American Society of Clinical Oncology.2020; 38: 1346–1366.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2019; 30: 1194–1220.
Martí, C.; Sánchez-Méndez, J.I. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers 2021, 13, 2538. https://doi.org/10.3390/cancers13112538
Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, et al. (2018) Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmeno-pausal ER positive and HER2 negative breast cancer. PLoS ONE 13(8): e0201846. doi:10.1371/journal.pone.0201846.
Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteris-tics. J Natl Cancer Inst. 2008; 100: 1380–1388. doi.:10.1093/jnci/djn309.
Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, et al. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 2024 Sep 24;26(1):138. doi: 10.1186/s13058-024-01883-w.
Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Res. 2023 Apr 12;25(1):39. doi: 10.1186/s13058-023-01626-3.
Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Japanese Journal of Clinical Oncology. 2019;49(4):329–338. doi: 10.1093/jjco/hyz012.
Xu W, Chen X, Deng F, Zhang J, Zhang W, Tang J. Predictors of neoadjuvant chemotherapy response in breast cancer a review. OncoTargets and Therapy. 2020;13(2020):5887–5899. doi: 10.2147/OTT.S253056.
Tan S, Fu X, Xu S, Qiu P, Lv Z, Xu Y, et al. Quantification of Ki67 change as a valid prognostic indicator of luminal B type breast cancer after neoadjuvant therapy. Pathology and Oncology Research. 2021;27(2021):1–16. doi: 10.3389/pore.2021.1609972.
Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, et al. Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer. JAMA Network Open. 2023;6(8):e2330961. doi: 10.1001/jamanetworkopen.2023.30961.
Miligy IM, Badr N, Stevens A, Spooner D, Awasthi R, Mir Y, et al. Pathological Changes Follow-ing Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers. Int J Mol Sci. 2024 Jul 5;25(13):7381. doi: 10.3390/ijms25137381.
Göker M, Denys H, Hendrix A, De Wever O, Van de Vijver K, Braems G. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer. Breast Cancer Res. 2023 Nov 22;25(1):146. doi: 10.1186/s13058-023-01745-x.
Petrelli F, Rea C, Parati MC, Borgonovo K, Ghilardi M, Dottorini L, et al. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis. Anticancer Res. 2023 Oct;43(10):4303-4313. doi: 10.21873/anticanres.16625.
Morrow M. Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer - Is It Obsolete? N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMe2414899.
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, et al. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063.
Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi:10.1001/jamaoncol.2023.3759.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.